Reference no: EM133857340
Case study
Increases in adverse clinical outcomes have been documented when hospital nurse staffing is inadequate. Since most hospitals limit nurse staffing to levels for average rather than peak patient census, substantial census increases create serious potential stresses for both patients and nurses. By reducing unnecessary variability, hospitals can reduce many of these stresses and thereby improve patient safety and quality of care.
The Source and Nature of Variability in Demand
The variability in the daily patient census is a combination of the natural (uncontrollable) variability contributed by the emergency department and the artificial (potentially controllable) peaks and valleys of patient flow into the hospital from elective admissions. Once artificial variability in demand is significantly reduced, a substantial portion of the peaks and valleys in census disappears; the remaining census variability is largely patient and disease driven. When artificial variability has been minimized, a hospital must have sufficient resources for the remaining patient-driven peaks in demand, over which it has no control, if it is to deliver an optimal level of care.
Discussion
Study of operational issues in health care delivery, and acting on what is learned, is critical. All forms of artificial variation in the demand and supply of health care services should be identified, and pilot programs to test operational changes should be conducted
Question 1. How effective is parathyroid hormone in the management of osteoporosis? Please explain the mechanism.
Question 2. 1. What is the recommended treatment for severe osteogenesis imperfecta?
2. Where two siblings have already been born with severe osteogenesis imperfecta, what is the risk of subsequent children of the same parents being born with this condition?
Question 3. Why does achondroplasia not affect the mandible (when all other bones are affected)?
Question 4. If an elderly patient with rheumatoid arthritis who has been taking myocrisin (injectable gold) for several years presents with pancytopenia, should the gold treatment be stopped? If so, what treatment should replace it?
Question 5. In a patient with dermatomyositis, what laboratory tests should be ordered to exclude systemic lupus erythematosus (SLE)?
Question 6. What treatment is recommended for tarsal tunnel syndrome?
Question 7. In a patient with documented antiphospholipid syndrome, should lupus anticoagulant be investigated for? If it is found to be present, will this necessitate the use of anticoagulants?
Question 8. What are the findings to be looked for during routine fundus examination in patients on long-term chloroquine or any other antimalarial therapy for the treatment of systemic lupus erythematosus (SLE)?
Question 9. What is the sensitivity of plain X-ray in detecting ankylosing spondylitisrelated spine lesions in both early and late disease, and is there a specific diagnostic test for this?
Question 10. It is reported by the Oxford Handbook of Clinical Medicine that glucosamine and chondroitin sulphate have failed an NEJM trial for the treatment of osteoarthritis? Is there still a valid use for these compounds?